PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 30, 2024Journal of Neurology Neurosurgery & Psychiatry4 citationsOpen Access

Impulse control disorders in Parkinson’s disease: a national Swedish registry study on high-risk treatments and vulnerable patient groups

View Full Paper
MWMirjam WolfschlagGWGustav Cedergren WeberDWDaniel Weintraub

Key Points

Key points are not available for this paper at this time.

Abstract

Background Impulse control disorders (ICDs) are known psychiatric conditions in Parkinson’s disease (PD), especially as a side effect of antiparkinsonian therapy. Screening for vulnerable patients and avoiding high-risk treatments can be an effective approach to reduce the ICD burden in patients with PD. Thus, our goal was to identify risk factors for ICDs in PD in the Swedish total population. Methods Our longitudinal study was based on records of all patients with PD in the Swedish National Patient Registries and the Prescribed Drug Register (n=55 235). Patients with incident gambling disorder and other ICDs were compared with a control group on demographic factors, psychiatric comorbidity, antiparkinsonian dopaminergic treatment and therapies for advanced disease. Potential risk factors were analysed using logistic regressions and relative frequency comparisons (Fisher’s exact test). Results Main predictors for incident gambling disorder were treatment with dopamine agonists (Frequency ratio 1.4, p=0.058), monoamine oxidase B (MAO-B) inhibitors (Frequency ratio 1.8, p=0.006) and a prescription for drugs used in addictive disorders (OR 5.85, 95% CI 2.00 to 17.10). Main predictors for other ICDs were dopamine agonist treatment (frequency ratio 1.6, p=0.003), anxiety disorders (OR 7.04, 95% CI 2.96 to 16.71) and substance use disorders other than alcohol (OR 5.66, 95% CI 1.75 to 18.23). Conclusions Our results support possible risk factors for incident ICDs that had previously been identified, like dopamine agonist treatment and raise additional attention for risk factors like MAO-B inhibitor treatment and specific psychiatric comorbidities. These findings enable tailoring antiparkinsonian therapy to individual patient-specific risk profiles.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wolfschlag et al. (2024) studied this question.

synapsesocial.com/papers/68e5e6f9b6db64358757bc0fhttps://doi.org/10.1136/jnnp-2024-334116
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevalence and clinical characteristics of impulse control disorder in Southern Brazilian Parkinson's disease patients2026
  2. 2Neuropsychological aspects of impulse control disorders in Parkinson’s disease2026 · 3 citations
  3. 3Impulse control disorders related cognitive and behavioral features in Parkinson’s disease2024
  4. 4Impulse Control Disorders in Parkinson’s Disease and Atypical Parkinsonian Syndromes—Is There a Difference?2024 · 3 citations
  5. 5Impulse control disorders and use of dopamine agonists in early onset Parkinson’s disease2024 · 6 citations